GuangYuYuan Chinese Herbal Medicine (600771) Fundamentals 2026 — P/E 105.7x, Revenue Analysis | SniperIQ
GuangYuYuan Chinese Herbal Medicine (600771) is a CN-listed Healthcare company in Drug Manufacturers - General with a market capitalization of ¥7.2B, trading at ¥14.67 on the SHH. This SniperIQ fundamentals page covers GuangYuYuan Chinese Herbal Medicine's valuation (P/E 105.7x, P/B 4.2x), profitability (net margin 4.6%), revenue (¥1.4B in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.
Full research coverage
- 8-Quarter Revenue & Margin Trend
- Debt Maturity & Coverage
- Peer Valuation Comparison
- Free Cash Flow & Owner Earnings
- AI Signal + Institutional Flow
- DCF Valuation Model
Frequently Asked Questions
What is GuangYuYuan Chinese Herbal Medicine's market cap?
GuangYuYuan Chinese Herbal Medicine (600771) has a market capitalization of approximately ¥7.2B, trading at ¥14.67 on the SHH. Market cap moves with the live share price.
What is GuangYuYuan Chinese Herbal Medicine's P/E ratio?
GuangYuYuan Chinese Herbal Medicine's trailing twelve-month P/E ratio is 105.7x, with a price-to-book (P/B) of 4.2x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
How profitable is GuangYuYuan Chinese Herbal Medicine?
GuangYuYuan Chinese Herbal Medicine runs a net profit margin of 4.6%, a gross margin of 67.8%, and an operating margin of 8.2%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
How much revenue does GuangYuYuan Chinese Herbal Medicine generate?
GuangYuYuan Chinese Herbal Medicine reported revenue of ¥1.4B for fiscal year 2025, with net income of ¥63M and earnings per share (EPS) of 0.13. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.
Does GuangYuYuan Chinese Herbal Medicine pay a dividend?
GuangYuYuan Chinese Herbal Medicine does not currently show a material trailing dividend yield; it is positioned more as a total-return name. Always confirm the latest dividend policy in the company's filings.
Is GuangYuYuan Chinese Herbal Medicine financially healthy?
GuangYuYuan Chinese Herbal Medicine carries a debt-to-equity ratio of 0.03x and a current ratio of 2.20x, with a market beta of 0.31. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is GuangYuYuan Chinese Herbal Medicine a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For GuangYuYuan Chinese Herbal Medicine (600771) the key facts are: market cap ¥7.2B, P/E 105.7x, revenue ¥1.4B, 52-week range 12.45-23.16. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.
Track GuangYuYuan Chinese Herbal Medicine's full fundamentals live
Get GuangYuYuan Chinese Herbal Medicine's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.